Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

723 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Exploring TCR-like CAR-Engineered Lymphocyte Cytotoxicity against MAGE-A4.
Alsalloum A, Shevchenko J, Fisher M, Philippova J, Perik-Zavodskii R, Perik-Zavodskaia O, Alrhmoun S, Lopatnikova J, Vasily K, Volynets M, Zavjalov E, Solovjeva O, Akahori Y, Shiku H, Silkov A, Sennikov S. Alsalloum A, et al. Among authors: shiku h. Int J Mol Sci. 2023 Oct 13;24(20):15134. doi: 10.3390/ijms242015134. Int J Mol Sci. 2023. PMID: 37894816 Free PMC article.
Dendritic cells transfected with a polyepitope DNA construct stimulate an antitumor cytotoxic response in various tumors.
Kurilin V, Kulikova E, Shevchenko J, Lopatnikova J, Obleukhova I, Khantakova J, Maksyutov A, Kuznetsova M, Khristin A, Kiryshina N, Kozlov V, Sidorov S, Sokolov A, Vitsin A, Shiku H, Sennikov S. Kurilin V, et al. Among authors: shiku h. Mol Clin Oncol. 2022 Oct 3;17(5):155. doi: 10.3892/mco.2022.2588. eCollection 2022 Nov. Mol Clin Oncol. 2022. PMID: 36325297 Free PMC article.
A phase 1 trial of NY-ESO-1-specific TCR-engineered T-cell therapy combined with a lymph node-targeting nanoparticulate peptide vaccine for the treatment of advanced soft tissue sarcoma.
Ishihara M, Nishida Y, Kitano S, Kawai A, Muraoka D, Momose F, Harada N, Miyahara Y, Seo N, Hattori H, Takada K, Emori M, Kakunaga S, Endo M, Matsumoto Y, Sasada T, Sato E, Yamada T, Matsumine A, Nagata Y, Watanabe T, Kageyama S, Shiku H. Ishihara M, et al. Among authors: shiku h. Int J Cancer. 2023 Jun 15;152(12):2554-2566. doi: 10.1002/ijc.34453. Epub 2023 Feb 17. Int J Cancer. 2023. PMID: 36727538 Clinical Trial.
Tumor Growth Suppression of Pancreatic Cancer Orthotopic Xenograft Model by CEA-Targeting CAR-T Cells.
Sato O, Tsuchikawa T, Kato T, Amaishi Y, Okamoto S, Mineno J, Takeuchi Y, Sasaki K, Nakamura T, Umemoto K, Suzuki T, Wang L, Wang Y, Hatanaka KC, Mitsuhashi T, Hatanaka Y, Shiku H, Hirano S. Sato O, et al. Among authors: shiku h. Cancers (Basel). 2023 Jan 18;15(3):601. doi: 10.3390/cancers15030601. Cancers (Basel). 2023. PMID: 36765558 Free PMC article.
Exhaustion, rather than lack of infiltration and persistence, of CAR-T cells hampers the efficacy of CAR-T therapy in an orthotopic PDAC xenograft model.
Takeuchi Y, Wang Y, Sasaki K, Sato O, Tsuchikawa T, Wang L, Amaishi Y, Okamoto S, Mineno J, Hirokawa Y, Hatanaka KC, Hatanaka Y, Kato T, Shiku H, Hirano S. Takeuchi Y, et al. Among authors: shiku h. Biomed Pharmacother. 2024 Jan;170:116052. doi: 10.1016/j.biopha.2023.116052. Epub 2023 Dec 22. Biomed Pharmacother. 2024. PMID: 38141280 Free article.
723 results